Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Looks to Rack Up Sales of 1.6 Trillion Yen in FY2025, 3 ADCs as Drivers
April 6, 2021
- Astellas, Toa Eiyo to End Sales Collaboration in March 2022
April 6, 2021
- Kowa Seeks 5.6 Billion Yen in Add’l Damages from Towa over Livalo Generics
April 6, 2021
- Viatris Launches New Headquarters in Tokyo
April 6, 2021
- Toho to Supply Nafamostat Free of Charge to Italian Physician-Led COVID-19 Trial
April 6, 2021
- Mochida’s Updated 3-Year Biz Plan Vows Continued Focus on New Meds
April 5, 2021
- Suzuken Unit Wins Wholesale Contract for Incyte’s Pemazyre
April 5, 2021
- Taiho’s Cholangiocarcinoma Drug Gets Breakthrough Therapy Tag from FDA
April 5, 2021
- Houng Kim to Lead Celltrion Healthcare Japan
April 5, 2021
- Takeda/CSL-Led Alliance’s COVID-19 Plasma Therapy Fails in PIII
April 5, 2021
- GSK Sees Promise in Antibody Therapy against Coronavirus Variants, Looking at Japan Rollout Too
April 2, 2021
- Alinamin Aims for Growth via Retail Promotion, Full Entry into Asia: President
April 2, 2021
- ASKA Sets Up Office in London
April 2, 2021
- Takeda Wraps Up Divestment of European OTC Biz
April 2, 2021
- Takeda Completes Divestment of 4 Diabetes Meds to Teijin in Japan
April 2, 2021
- Mitsubishi Tanabe Wins US Patent Suit on Canagliflozin
April 2, 2021
- Viatris, Astellas to Wind Up Lipitor Copromotion at July-End
April 2, 2021
- Sandoz Shooting for Top Foreign Player in Japan Generic Market by 2023
April 1, 2021
- Fujifilm Holdings Names Teiichi Goto New President
April 1, 2021
- Eisai Snags Rights to Vibegron in 4 ASEAN States
April 1, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…